Aug 20, 2022 02:23 AM

BUSINESS

Pfizer Signs China Partnership to Make Paxlovid Covid Pills Locally

By Qi Zhanning and Han Wei

Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.

Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.

Chinese drugmaker Zhejiang Huahai Pharmaceutical Co. Ltd. has entered an agreement with Pfizer Inc. to manufacture the U.S. giant’s Covid-19 pill Paxlovid in China.

Shanghai-listed Huahai Pharmaceutical said Thursday that it has signed a non-exclusive production and supply agreement with the Chinese subsidiary of Pfizer. Under the agreement, Huahai Pharmaceutical will produce Paxlovid in China for five years.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Capturing Watershed Moments of 2022

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin China Biz Roundup: Auto Sector Price War Heats Up

00:00

00:00/00:00

MOST POPULAR

1: South Korea’s Hanwha Wins Three More Approvals for Daewoo Shipbuilding Deal

2: Chinese Police Arrest Multiple Pro Soccer Players

3: The China Price War That Tesla Started May Wipe Out Some Carmakers

4: Exclusive: Meituan Co-Founder’s AI Startup to Buy OneFlow Technology

5: Saudi Aramco Boosts China Investment With $3.6 Billion Refinery Deal

SPONSORED

OR